Skip to content
Combined Shape Created with Sketch.
  • COVID-19
  • EyewireTV
  • Stocks
  • Interests
    • Cataract and Refractive Eye-Grey Created with Sketch.
    • Glaucoma Gauge-Grey Created with Sketch.
    • Healthcare Cross-Grey Created with Sketch.
    • Optometry Laser-Grey Created with Sketch.
    • Product Approvals Gear-Grey Created with Sketch.
    • Retina Laser-Grey Created with Sketch.
  • More
    • Events
    • Subscribe
    • About
    • Send a Tip
    • Advertising
    • Privacy Policy
  • COVID-19
  • EyewireTV
  • Stocks
  • Interests
    • Cataract and Refractive Eye-Grey Created with Sketch.
    • Glaucoma Gauge-Grey Created with Sketch.
    • Healthcare Cross-Grey Created with Sketch.
    • Optometry Laser-Grey Created with Sketch.
    • Product Approvals Gear-Grey Created with Sketch.
    • Retina Laser-Grey Created with Sketch.
  • Events
  • About
  • Send a Tip
  • Advertising
  • Privacy Policy

Bausch Health

02.22.21

Bausch Health To Reduce Debt By $100 Million Using Cash Generated From Operations

Source: Bausch Health

02.15.21

Icahn to Push for Changes at Bausch Health After Disclosing Stake

Source: FirstWord

02.09.21

Bausch Health Announces Vyzulta is Now Approved in South Korea

Source: Bausch Health

11.16.20

B+L: Investigational In Vitro Data Indicates Complete Inactivation Of SARS-CoV-2 With Lumify and Besivance Eye Drops

Source: Bausch Health

10.15.20

Bausch Health and BHVI Announce Global Licensing Agreement For Myopia Control Contact Lens

Source: Bausch Health

10.12.20

Bausch Health Licenses Eyenovia’s Investigational Treatment For The Reduction Of Pediatric Myopia Progression In Children Ages 3-12

Source: Bausch Health

09.25.20

FDA Approves Bausch + Lomb Alaway Preservative Free OTC Drops

Source: Bausch Health

09.24.20

Bausch Health Announces Vyzulta Now Approved in Seven Countries; Expanded Coverage in Canada

Source: Bausch Health

09.21.20

Bausch Health Acquires Option To Purchase Ophthalmology Assets Of Allegro Ophthalmics

Source: Bausch Health

04.28.20

Clearside Biomedical Revises NDA Resubmission Timeline and Xipere Commercial Partnership with Bausch Health

Source: Clearside Biomedical

View more stories

Home

Menu

Share

  • Cataract and Refractive
  • Cornea
  • Glaucoma
  • Healthcare
  • Innovation
  • Optometry
  • Product Approvals
  • Retina
  • Events
  • About
  • Send a Tip
  • Advertising
  • Contact
  • EyewireTV
  • Stocks
  • Privacy Policy
Created with Sketch. Created with Sketch. Created with Sketch. Created with Sketch.
eyewire-news-color bmc-mark Created with Sketch.

© 2021 Bryn Mawr Communications, LLC.

All Rights Reserved.